Risk of nonlower respiratory serious adverse events following COPD exacerbations in the 4-year UPLIFT® trial
Halpin, David M G × Decramer, Marc Celli, Bartolome Kesten, Steven Leimer, Inge Tashkin, Donald P #
Lung vol:189 issue:4 pages:261-268
Chronic obstructive pulmonary disease (COPD) exacerbations are associated with systemic consequences. Data from a 4-year trial (Understanding Potential Long-term Impacts on Function with Tiotropium [UPLIFT(®)], n = 5,992) were used to determine risk for nonlower respiratory serious adverse events (NRSAEs) following an exacerbation.